Salarius Pharmaceuticals: Q1 Earnings Insights Salarius Pharmaceuticals (NASDAQ:SLRX) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Benzinga · May 12, 2022
Salarius Pharmaceuticals Successfully Completes pre-IND Meeting with FDA for SP-3164 Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) successfully completed the pre-IND (Investigational New Drug) meeting process with the U.S. Food and Drug Administration (FDA) for SP-3164 in hematological cancers and solid tumors. Benzinga · May 11, 2022
Salarius Pharmaceuticals's Earnings: A Preview Salarius Pharmaceuticals (NASDAQ:SLRX) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that Salarius Pharmaceuticals will report an earnings per share (EPS) of $-0.09. Benzinga · May 11, 2022
Salarius Pharmaceuticals: Q4 Earnings Insights Salarius Pharmaceuticals (NASDAQ:SLRX) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Benzinga · Mar 10, 2022
Salarius Pharmaceuticals's Earnings: A Preview Salarius Pharmaceuticals (NASDAQ:SLRX) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement. Analysts estimate that Salarius Pharmaceuticals will report an earnings per share (EPS) of $-0.08. Benzinga · Mar 9, 2022